MRK Stock Recent News

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29.

Merck: Don't Let Today's Bargain Opportunity Pass You By

Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting the urgent need for diversification.

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipeline. Earlier this month, we highlighted how Keytruda is a ticking time bomb for Merck stock.

Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP Recommends Merck's ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season.

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.

Health and Human Services Secretary Robert F. Kennedy Jr.'s revamped government panel of vaccine advisors recommended the use of Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus.

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news from the CDC.

An advisory panel of the U.S. Centers for Disease Control and Prevention on Thursday recommended the use of Merck's respiratory syncytial virus therapy, Enflonsia, for infants 8 months or younger, whose mother did not receive a preventive shot during pregnancy.